Biologics vs. JAK Inhibitors for Atopic Dermatitis: Which One Wins for Your Patient? A 2026 Practical Guide 3/08/2026 Atopic Dermatitis Biologics Dupilumab JAK inhibitors +
2025: A Breakthrough Year for Chronic Urticaria - New FDA Approvals Reshaped Treatment 3/07/2026 Dupilumab Remibrutinib Urticaria +
Revolutionizing Respiratory Care: How Type 2 Biologics Are Changing the Game for Severe Asthma and Beyond 3/06/2026
Tezepelumab in Real-World Danish Severe Asthma Study: Benefits Even After Biologic Switches 3/04/2026 Asthma Biologics Tezepelumab +
Tezepelumab vs. Dupilumab in Severe Asthma: Head-to-Head Real-World Data Shows No Clear Winner 3/03/2026 Asthma Biologics Dupilumab Tezepelumab +
Omalizumab Helps High-Risk Patients Tolerate Honeybee Venom Allergy Shots 3/02/2026 Immunotherapy Insects Omalizumab Venom Allergy +
Dupilumab-Induced Eosinophilia (DIBE) in CRSwNP Affected 48% of Patients 3/01/2026 Chronis Sinusitis Dupilumab Eosinophilia +
Why Some Chronic Hives Patients May Not Respond Well to Omalizumab: New Biopredictors Identified 2/28/2026 Urticaria +
Staph Aureus on the Skin Associated With Severe Food Allergic Reactions Via a Cascade: IL-33, IL-3, IL-4 2/22/2026 Atopic Dermatitis Food Allergy +
New Risk Score Predicts Nasal Polyp Recurrence After Sinus Surgery for CRSwNP 2/20/2026 Chronis Sinusitis +
Monoclonal Antibody Targeting OX40L (Amlitelimab) In Development for Atopic Dermatitis 2/18/2026 Atopic Dermatitis +
EoE Pipeline Update: Dupilumab Leads, But Exciting Contenders Are Closing In 2/17/2026 Eosinophilic esophagitis +